ISSN:
1432-0843
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Medizin
Notizen:
Summary A phase I and pharmacokinetic study of a novel lipid-soluble antifolate, 2,4 diamino-5-adamanty-6-methyl pyrimidine ethane sulfonate (DAMP-ES) has been carried out on two schedules: I—dailyx5; II—24-h continuous infusion. In schedule I, doses of 10–90 mg/m2 per day were evaluated. Dose-limiting toxicity was hematologic, but nausea and vomiting, skin rash, diarrhea, anorexia, alopecia, mucositis, and neurotoxicity were also noted. In schedule II, doses of 192 and 240 mg/m2 were evaluated. Dose-limiting toxicity was neurotoxicity, but hematologic toxicity was also marked. Recommended starting doses for phase II studies are 75 mg/m2 per day for 5 days or 192 mg/m2 by continuous infusion for 24 h. Pharmacokinetic studies indicated a β-phase plasma half-life of 12.4–24 h and a large and variable volume of distribution.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1007/BF00257357